Analyst Note: Goldman cautious on Abbott, Lilly
(AP:NEW YORK) A Goldman Sachs analyst reaffirmed her outlook for Abbott Laboratories and Eli Lilly & Co., but expressed more caution on her respective ratings, citing a mix of drug sales and operating performances in the coming year.
2009-12-01 -
INO News